Live Breaking News & Updates on Viatris Pharmaceuticals Japan Inc

Stay updated with breaking news from Viatris pharmaceuticals japan inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

2022: Successful transformation into a commercial stage company - Form 6-K

2022: Successful transformation into a commercial stage company

"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for. | February 23, 2023 ....

United States , United Kingdom , Marie Galay , Kidney International , Viatris Pharmaceuticals Japan , Viatris Pharmaceuticals Japan Inc , European Commission , European Commission For Kinpeygo , American Society Of Nephrology , National Medical Products Administration , European Union Member States , American Society , Kidney Week , Everest Medicines , New Drug Application , Priority Review , China Everest Medicine , Events After , Reporting Period , Conditional Marketing Authorization , European Economic Area , Presentation February , Nasdaq Stockholm , American Depositary Shares , Nasdaq Global Select Market , Calliditas Therapeutics Ab Publ Stock Exchange ,

Calliditas - Year-End Report, 2022 (2)

"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA. ....

United States , United Kingdom , Marie Galay , Kidney International , Viatris Pharmaceuticals Japan , Viatris Pharmaceuticals Japan Inc , European Commission , European Commission For Kinpeygo , Exchange Commission , American Society Of Nephrology , National Medical Products Administration , European Union Member States , American Society , Kidney Week , Everest Medicines , New Drug Application , Priority Review , China Everest Medicine , Events After , Reporting Period , Conditional Marketing Authorization , European Economic Area , Presentation February , Calliditas Tel , Nasdaq Stockholm , American Depositary Shares ,

Calliditas - Year-End Report, 2022 (1)

"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA. ....

United States , United Kingdom , Marie Galay , Kidney International , Viatris Pharmaceuticals Japan , Viatris Pharmaceuticals Japan Inc , European Commission , European Commission For Kinpeygo , Exchange Commission , American Society Of Nephrology , National Medical Products Administration , European Union Member States , American Society , Kidney Week , Everest Medicines , New Drug Application , Priority Review , China Everest Medicine , Events After , Reporting Period , Conditional Marketing Authorization , European Economic Area , Presentation February , Calliditas Tel , Nasdaq Stockholm , American Depositary Shares ,

Calliditas - Year-End Report, 2022

/PRNewswire/ "2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA nephropathy and a medication with. ....

United States , United Kingdom , Marie Galay , Kidney International , Viatris Pharmaceuticals Japan , Viatris Pharmaceuticals Japan Inc , European Commission , European Commission For Kinpeygo , Exchange Commission , American Society Of Nephrology , National Medical Products Administration , European Union Member States , American Society , Kidney Week , Everest Medicines , New Drug Application , Priority Review , China Everest Medicine , Events After , Reporting Period , Conditional Marketing Authorization , European Economic Area , Presentation February , Nasdaq Stockholm , American Depositary Shares , Nasdaq Global Select Market ,

Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan

/PRNewswire/ Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") announced today that they have entered into an exclusive. ....

United States , Marie Galay , Exchange Commission , Viatris Pharmaceuticals Japan Inc , European Commission , European Union Member States , Viatris Inc , Global Healthcare , Nasdaq Stockholm , American Depositary Shares , Nasdaq Global Select Market , Private Securities Litigation Reform Act , Calliditas Therapeutics ,